Abstracts Archive - Page 539 of 2607 - ACR Meeting Abstracts

Abstract Number: 2602 • ACR Convergence 2023
Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis
Cecilia Ansalone¹, Sam McAllister², Ethan Pickerill³, Lin Zhang³, Annie Peacock², Dominic McGovern⁴, Holly Leslie⁵, Victoria Kellior², Evelyn Qian², David Gemperline³, Aysin Tulunay Virlan², Sylvia Wright⁶, Paul Cauchi⁶, Timothy Beckman⁶, Lisa Hutton⁶, John Cole¹, Isabella Wulur³, Robert Benschop³, Nigel Jamieson⁵, Carl Goodyear¹ and Neil Basu¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Glasgow - School of Medicine, Glasgow, United Kingdom, ⁵University of Glasgow - School of Cancer Sciences, Glasgow, United Kingdom, ⁶NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Background/Purpose: Corticosteroids (CS) remain the mainstay of giant cell arteritis (GCA) therapy. Between ~30-70% patients relapse following CS taper and are consequently at risk of…
Abstract Number: PP11 • ACR Convergence 2023
We Suffered For Decades, But Then She Was Born
Ian Stedman¹ and Barbara Stedman², ¹Canadian Autoinflammatory Network, Vaughan, ON, Canada, ²Canadian Autoinflammatory Network, Turkey Point, ON, Canada
Background/Purpose: I was born in 1981; my mother in 1949; and my grandmother in 1926. Our story runs at least four generations deep, that we…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: PP06 • ACR Convergence 2023
Dana’s Data Dashboard: Applying a Familiar Framework for Efficient and Effective Health Management
Dana Guglielmo, Los Angeles, CA
Background/Purpose: As a researcher and data analyst, I enjoy the meticulous attention to detail that my work requires. I love the process of collecting, analyzing,…
Abstract Number: 2477 • ACR Convergence 2023
Anifrolumab Normalizes the Type I Interferon Signature in a Cohort of Patients with Type I Interferonopathies
Sara Alehashemi¹, Alexi Baumgardner², Bita Shakoory³, Adriana Almeida de Jesus², Sophia Park², Kat Uss², Maria P. Robles⁴, Karin Palmblad⁵, Annacarine Horne⁵, Peter Brodin⁵, Shoghik Akoghlanian⁶, Roshini Abraham⁷, Peter Mustillo⁷, Lilliana Barillas-Arias⁸, Andrea Heras⁹, Theresa Wampler Muskardin¹⁰, Monica G. Lawrence¹¹, Hannah C. Mannem¹¹, Brian E. Nolan¹², Scott Canna¹³, Adam Reinhardt¹⁴, Bryce Binstadt¹⁵ and Raphaela Goldbach-Mansky¹⁶, ¹NIH/NIAID/TADS, Clarksville, MD, ²NIAID, NIH, Bethesda, MD, ³NIH, NIAID, Translational Autoinflammatory Disease Study Unit, Bethesda, MD, ⁴Indiana University, Indianapolis, IN, ⁵Karolinska University Hospital, Stockholm, Sweden, ⁶Nationwide Children's Hospital, Columbus, OH, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸Albany Medical Center, Albany, NY, ⁹Weill Cornell Medicine, New York, NY, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Virginia, Charlottesville, VA, ¹²Lurie Children’s Hospital, Chicago, IL, ¹³Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁴Boys Town National Research Hospital, Omaha, NE, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶NIH/NIAID, Potomac, MD
Background/Purpose: Autoinflammatory Type I Interferonopathies (IFNopathies) include SAVI (STING-associated vasculopathy with onset in infancy), CANDLE/PRASS (Chronic atypical neutrophilic dermatosis, with lipodystrophy and elevated temperature), and…
Abstract Number: 2604 • ACR Convergence 2023
Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis
Chenglong Fang¹, Lihong Du¹, Lili Li², Yuexin Chen³, Zuoguan Chen⁴, Yongjun Li⁴, Jing Li¹, Mengtao Li⁵, xiaofeng Zeng⁶ and Xinping Tian⁵, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²The State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China, ³Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁴Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by persistent vascular inflammation involving aorta and its main branches, which is an important prosenescent factor that in turn…
Abstract Number: 2252 • ACR Convergence 2023
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
William R Tillett¹, Joseph Merola², Yoshiya Tanaka³, Ennio G Favalli⁴, Dennis McGonagle⁵, Diamant Thaçi⁶, Jessica A Walsh⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jason Coarse⁹ and Christopher T Ritchlin¹⁰, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁷Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Morrisville, NC, ¹⁰University of Rochester Medical School, Rochester, NY
Background/Purpose: PsA is a chronic disease affecting multiple domains; however, patients (pts) can experience loss of response with long-term therapy.1 Therefore, maintaining long-term treatment responses…
Abstract Number: 2251 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Koji Kato⁶, Arathi Setty⁶, Tianming Gao⁶, Diane Caballero⁷, Ralph Lippe⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie, Inc., Chicago, IL, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Pain, including inflammatory joint pain, may be debilitating in patients with psoriatic arthritis (PsA). Pain in PsA is multidimensional and can be influenced via…
Abstract Number: PP10 • ACR Convergence 2023
Saved by Plants: How a Necessary Lifestyle Change Led to a Happier Life with Decreased Rheumatoid Arthritis Pain and Fatigue
Shelley Fritz, Global Healthy Living Foundation, Nyack, NY
Background/Purpose: After my RA diagnosis over eleven years ago, I was optimistic that the first biologic DMARD I took would slow the progression of my…
Abstract Number: 2487 • ACR Convergence 2023
Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity
Nan Shen¹, Stanislav Ignatenko², Alexander Gordienko³, Josefina Cortés Hernández⁴, Nancy Agmon-Levin⁵, Pongthorn Narongroeknawin⁶, Katarzyna Romanowska -Prochnicka⁷, Hana Ciferska⁸, Masanari Kodera⁹, James Cheng-Chung Wei¹⁰, Piotr Leszczynski¹¹, Joung-Liang Lan¹², Eduardo Mysler¹³, Rafal Wojciechowski¹⁴, Tunde Tarr¹⁵, Elena Vishneva¹⁶, Yi-Hsing Chen¹⁷, Yuko Kaneko¹⁸, Stephanie Finzel¹⁹, Alberta Hoi²⁰, Ajchara Koolvisoot²¹, Shin-Seok Lee²², Lie Dai²³, Hiroshi Kaneko²⁴, Bernadette Rojkovich²⁵, Lingyun Sun²⁶, Eugeny Zotkin²⁷, Jean-Francois Viallard²⁸, Masao Katayama²⁹, Berta Paula Magallares-Lopez³⁰, Tirtha Sengupta³¹, Carol Sips³² and Stephen J Oliver³², ¹Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ²Charité Research Organisation GmbH, Berlin, Germany, ³SM Kirov Military Medical Academy, St. Petersburg, Russia, ⁴Lupus Unit, Rheumatology Department, Vall d’Hebron Hospitals, Barcelona, Spain, ⁵Yabludowicz Center for Autoimmune Disease, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁶Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand, ⁷Department of Systemic Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹Department of Dermatology, Japan Community Healthcare Organization Chukyo Hospital, Nagoya, Japan, ¹⁰Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ¹¹Department of Internal Medicine, Poznan University of Medicine Sciences, Poznan, PL, Poznań, Poland, ¹²China Medical University Hospital, Taichung, Taiwan, ¹³Organizacion Medica de Investigacion, Buenos Aires, Argentina, ¹⁴Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, Poland, ¹⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ¹⁶LLC Family Clinic, Yekaterinburg, RU, Yekaterinburg, Russia, ¹⁷Taichung Veterans General Hospital, Taichung, Taiwan, ¹⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ²⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ²¹Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²²Chonnam National University Medical School & Hospital, Gwangju, South Korea, ²³Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ²⁴Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, Japan, ²⁵Department of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers of St. John of God, Semmelweis University, Budapest, Hungary, ²⁶Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²⁷VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ²⁸CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, ²⁹National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, ³⁰Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ³¹Novartis Pharma India, Hyderabad, Hyderabad, India, ³²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab is a novel defucosylated human IgG1 mAb targeting the receptor for B cell Activating Factor belonging to the TNF Family (BAFF-R) providing potent…
Abstract Number: 2262 • ACR Convergence 2023
Identifying Important Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Results of a Modified Delphi Study
Kathryn Connelly¹, Rachel Koelmeyer¹, Darshini Ayton¹, Raychel Barrallon¹, Laura Eades², Vera Golder³, Kate gregory¹, John May¹, Rangi Kandane-Rathnayake³, Maisarah Mydin¹, Munni Akther¹, Afia Anzum¹, Jeanette Andersen⁴, Hermine Brunner⁵, Cynthia Aranow⁶, Laurent Arnaud⁷, Anca Askanase⁸, Catherine Barbey⁹, Joy Buie¹⁰, Laurie Burke¹¹, Alain Cornet¹², Karen Costenbader¹³, Maria Dall'Era¹⁴, Joan Merrill¹⁵, Khadija Dantata¹⁶, Alan Friedman¹⁷, Richard Furie¹⁸, Sandra Garces¹⁹, Maja Hojnik²⁰, Kenneth Kalunian²¹, Justine Maller²², Patrick Marquis²³, Marta Mosca²⁴, Erika Noss²⁵, Guillermo Pons-Estel²⁶, Lee Simon²⁷, Eve Smith²⁸, Alessandro Sorrentino²⁹, Anna Stevens³⁰, George Stojan³¹, Ying Sun³², Yoshiya Tanaka³³, Ed Vital³⁴, Ronald van Vollenhoven³⁵, Victoria P. Werth³⁶ and Eric Morand³⁷, ¹Monash University, Clayton, Australia, ²Monash Health and Monash University, Clayton, Australia, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Lupus Europe, Knebel, Denmark, ⁵Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷University Hospitals of Strasbourg, Strasbourg, France, ⁸Columbia University Medical Center, New York, NY, ⁹Biogen, Baar, Switzerland, ¹⁰Lupus Foundation of America, York, SC, ¹¹LORA Group, Normal, IL, ¹²Lupus Europe, Brussels, Belgium, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Lupus Foundation of America, Richmond Hill, GA, ¹⁷AbbVie, Inc., North Chicago, IL, ¹⁸Northwell Health, Manhasset, NY, ¹⁹Amgen, Inc., Thousand Oaks, CA, ²⁰Eli Lilly and Company, Indianapolis, IN, ²¹University of California San Diego, La Jolla, CA, ²²Genentech, Inc., Half Moon Bay, CA, ²³Modus Outcomes, Newton, MA, ²⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²⁵Janssen Research and Development, Dresher, PA, ²⁶CREAR, Rosario, Argentina, ²⁷SDG LLC, West Newton, MA, ²⁸University of Liverpool, Liverpool, United Kingdom, ²⁹Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ³⁰Bristol Myers Squibb, Groton, CT, ³¹UCB, Baltimore, MD, ³²the healthcare business of Merck KGaA, Darmstadt, Germany, ³³University of Occupational and Environmental Health, Kitakyushu, Japan, ³⁴University of Leeds, Leeds, United Kingdom, ³⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ³⁶University of Pennsylvania, Wynnewood, PA, ³⁷Monash University, Centre for Inflammatory Diseases, Melbourne, Australia
Background/Purpose: The Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE) is a novel clinical outcome assessment (COA) for SLE randomized controlled trials (RCTs), being developed…
Abstract Number: 2260 • ACR Convergence 2023
Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Yuichiro fujieda¹, Kodai Sakiyama¹, Nobuya Abe¹, Ryo Hisada¹, Michihito Kono¹, Masaru Kato¹, Olga Amengual², Khin Khin Tha³, Hisashi Shirakawa⁴ and Tatsuya Atsuma⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan, ³Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto, Japan, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan
Background/Purpose: Fatigue is a common symptom in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Resting-state functional magnetic resonance imaging (rs-fMRI) has…
Abstract Number: 2240 • ACR Convergence 2023
Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
Aisha Vadhariya¹, Sarah Ross¹, Brenna Brady², Helen Varker², Anh Thu Tran² and Jessica A Walsh³, ¹Eli Lilly and Company, Indianapolis, IN, ²Merative, Cambridge, MA, ³Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: The treatment paradigm for psoriatic arthritis (PsA) has changed over the last two decades, with increasing numbers of therapy options that target a variety…
Abstract Number: 2250 • ACR Convergence 2023
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
Dafna Gladman¹, Laure Gossec², M. Elaine Husni³, Lars Erik⁴, Paolo Gisondi⁵, Alice B. Gottlieb⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jérémy Lambert⁹, Nikos Lyris⁸, Jason Coarse¹⁰ and William R Tillett¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Università di Verona, Verona, Italy, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Irigny, France, ¹⁰UCB Pharma, Morrisville, NC, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA has a substantial negative impact on patient (pt) health-related quality of life (HRQoL);1 symptom control, preventing structural damage, and normalizing physical and social…
Abstract Number: 2263 • ACR Convergence 2023
Disease Activity Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Eric Morand¹, Richard Furie², Christine Peschken³, Martin Aringer⁴, Laurent Arnaud⁵, Barnabas Desta⁶, Tina Grünfeld Eén⁷, Alessandro Sorrentino⁸, Stephanie Chen⁹ and Bo Ding⁷, ¹Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ²Northwell Health, Manhasset, NY, ³University of Manitoba, Winnipeg, MB, Canada, ⁴Carl Gustav Carus, Dresden, Germany, ⁵University Hospitals of Strasbourg, Strasbourg, France, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁸Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: The international, multicenter SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with SLE in relation to their type 1 interferon gene signature…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].